LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor**

The bromodomain-containing proteins BRD9 and BRD7 are part of the human SWI/SNF chromatin-remodeling complexes BAF and PBAF. To date, no selective inhibitor for BRD7/9 has been reported despite its potential value as a biological tool or as a lead for future therapeutics. The quinolone-fused lactam LP99 is now reported as the first potent and selective inhibitor of the BRD7 and BRD9 bromodomains. Development of LP99 from a fragment hit was expedited through balancing structure-based inhibitor design and biophysical characterization against tractable chemical synthesis: Complexity-building nitro-Mannich/lactamization cascade processes allowed for early structure–activity relationship studies whereas an enantioselective organocatalytic nitro-Mannich reaction enabled the synthesis of the lead scaffold in enantioenriched form and on scale. This epigenetic probe was shown to inhibit the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. Moreover, LP99 was used to demonstrate that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion.

[1]  T. Mutai,et al.  Design of a fluorescent host for monitoring multiple hydrogen-bonding interaction directly by intramolecular charge-transfer emission , 1998 .

[2]  Dimitris Thanos,et al.  Ordered Recruitment of Chromatin Modifying and General Transcription Factors to the IFN-β Promoter , 2000, Cell.

[3]  S. Buchwald,et al.  Pd-catalyzed intermolecular amidation of aryl halides: the discovery that xantphos can be trans-chelating in a palladium complex. , 2002, Journal of the American Chemical Society.

[4]  J. Findlay,et al.  1-Aryl-3,4-dihydro-1H-quinolin-2-one derivatives, novel and selective norepinephrine reuptake inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[5]  S. Smale,et al.  Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. , 2006, Genes & development.

[6]  M. Mansukhani,et al.  Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha , 2008, Molecular Cancer.

[7]  S. Ponnappan,et al.  Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes. , 2009, Molecular immunology.

[8]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[9]  K. Nicolaou,et al.  The art of total synthesis through cascade reactions. , 2009, Chemical Society reviews.

[10]  György G Ferenczy,et al.  Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.

[11]  Niamh M. Ryan,et al.  BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. , 2010, Cancer research.

[12]  R. Elkon,et al.  BRD7 is a candidate tumour suppressor gene required for p53 function , 2010, Nature Cell Biology.

[13]  J. Raftery,et al.  Stereoselective, nitro-Mannich/lactamisation cascades for the direct synthesis of heavily decorated 5-nitropiperidin-2-ones and related heterocycles , 2012, Beilstein journal of organic chemistry.

[14]  D. Dixon,et al.  A new family of cinchona-derived bifunctional asymmetric phase-transfer catalysts: application to the enantio- and diastereoselective nitro-Mannich reaction of amidosulfones. , 2012, Organic letters.

[15]  R. Xu,et al.  Prognostic relevance of BRD7 expression in colorectal carcinoma , 2013, European journal of clinical investigation.

[16]  E. Solary,et al.  TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS , 2013, The EMBO journal.

[17]  L. Cantley,et al.  BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity. , 2014, Molecular cell.

[18]  S. Knapp,et al.  [1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains , 2013, Journal of medicinal chemistry.

[19]  A. Gingras,et al.  Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching , 2014, Epigenetics & Chromatin.

[20]  Structure-based approaches towards identification of fragments for the low-druggability ATAD2 bromodomain , 2014 .

[21]  Julien Rossignol,et al.  Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography , 2014 .

[22]  G. Keserű,et al.  Is there a link between selectivity and binding thermodynamics profiles? , 2015, Drug discovery today.